Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics

Cancer Research

Volumn 68, Issue 20, 2008, Pages 8384-8392

  Rossi, Edmund A ^a   Goldenberg, David M ^c,d   Cardillo, Thomas M ^b   Stein, Rhona ^c   Wang, Yang ^b   Chang, Chien Hsing ^a,b  

^a IBC Pharmaceuticals Inc   (United States)

^b IMMUNOMEDICS INC   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^d GARDEN STATE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CD20 ANTIBODY; EPRATUZUMAB; HEX HA20 ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; LABETUZUMAB; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB; UNCLASSIFIED DRUG; VELTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CALCIUM MOBILIZATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; CROSS LINKING; DAUDI CELL; DRUG HALF LIFE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID RAFT; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAJI CELL; SITE DIRECTED MUTAGENESIS; THERAPY EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; APOPTOSIS; CALCIUM; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; LYMPHOMA; MICE; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 54249124592     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2033     Document Type: Article

References (44)

1. Martin P, Furman RR, Ruan J, et al. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Semin Hematol 2008;45:126-32.
2. Goldblatt F, Isenberg DA. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus. Handb Exp Pharmacol 2008;181:163-81.
3. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphoma. Blood 2004;104:1793-800.
4. Umana P, Moessner E, Bruenker P, et al. Novel third generation humanized type II CD20 antibody with superior direct cell death induction and glycoengineered Fc region for enhanced ADCC induction. Blood 2006;108:Abstract #229.
5. Glennie MJ. French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37.
6. Shuford W, Raff HV, Finley JW, Esselstyn J, Harris LJ. Effect of light chain V region duplication on IgG oligomerization and in vivo efficacy. Science 1991;252:724-7.
7. Shopes B. A genetically engineered human IgG mutant with enhanced cytolytic activity. J Immunol 1992;148:2918-22.
8. Caron PC, Laird W, Co MS, Avdalovic NM, Queen C, Scheinberg DA. Engineered humanized dimeric forms of IgG are more effective antibodies. J Exp Med 1992;176:1191-5.
9. Wolff EA, Schreiber GJ, Cosand WL, Raff HV. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res 1993;53:2560-5.
10. Ng PP, Cruz JSD, Sorour DN, et al. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A 2002;99:10706-11.
11. Ghetie M-A, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis oftumor cells. Proc Natl Acad Sci U S A 1997;94:7509-14.
12. Ghetie M-A, Bright H, Vitetta ES. Homodimers but not monomers of rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001;97:1392-8.
13. Huang TH, Morrison SL. A trimeric anti-HER2/neu scFv and tumor necrosis factor-α fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia. J Pharmacol Exp Ther 2006;316:983-91.
14. Meng R, Smallshaw JE, Pop LM, et al. The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies. Clin Cancer Res 2004;10:1274-81.
15. Liu XY, Pop LM, Roopenian DC, Ghetie V, Vitetta ES, Smallshaw JE. Generation and characterization of a novel tetravalent anti-CD22 antibody with improved antitumor activity and pharmacokinetics. Int Immunopharmacol 2006;6:791-9.
16. Li B, Shi S, Qian W, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res 2008;68:2400-8.
17. Zhang N, Khawli LA, Hu P, Epstein AL. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphoma. Clin Cancer Res 2005;11:5971-80.
18. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody. IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin' s lymphoma. Clin Cancer Res 2004;10:2868-78.
19. Morschhauser F, Leonard JP, Fayad LE, et al. Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: phase I/II results [Abstr. #8032]. J Clin Oncol 2007;25:449s.
20. Baillie GS, Scott JD, Houslay MD. Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Letters 2005;579:3264-70.
21. Wong W, Scott JD. AKAP signaling complexes: focal points in space and time. Nat Rev Mol Cell Biol 2004;5:959-70.
22. Rossi, EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A 2006;103:6841-6.
23. Chang CH, Rossi EA, Goldenberg DM. The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res 2007;13:5586-91s.
24. Qu Z, Griffiths GL, Wegener WA, et al. Development of humanized antibodies as cancer therapeutics. Methods 2005;36:84-95.
25. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002;99:3256-62.
26. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003;9:5866-73.
27. van der Kolk LE, Evers LM, Omene C, et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 2002;16:1735-44.
28. Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang C-H. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 2008;111:2211-9.
29. Mone AP, Cheney C, Banks AL, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006;20:272-9.
30. Miller K, Meng G, Liu J, et al. Design, construction, and in vitro analysis of multivalent antibodies. J Immunol 2003;170:4854-61.
31. Jendreyko N, Popkov M, Beerli RR, et al. Intrabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J Biol Chem 2003;278:47812-9.
32. Shen J, Vil MD, Jimenez X, Iacolina M, Zhang H, Zhu Z. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies. J Biol Chem 2006;281:10706-14.
33. Shen J, Vil MD, Jimenez X, et al. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. J Immunol Methods 2007;318:65-74.
34. Wu C, Yinh H, Grinnell C, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotech 2007;25:1290-7.
35. Cragg MS, Morgan SM, Chan HT et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-52.
36. 2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51:15-24.
37. Unruh TL, Li H, Mutch CM, et al. Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. Immunology 2005;116:223-32.
38. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induces apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase-dependent apoptosis. Blood Cells Mol Dis 2000;26:133-43.
39. Deans JP, Polyak MJ. CD20-mediated apoptosis: signaling through lipid rafts. Immunology 2002;107:176-82.
40. Li H, Ayer LM, Polyak MJ, et al. The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism. J Biol Chem 2004;279:19893-901.
41. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71.
42. Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, Vandlen RL. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005;44:15150-8.
43. Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem 2007;282:15073-80.
44. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91:1644-52.